1. 2021 Alzheimer's disease facts and figures. Alzheimers Dement 2021;17:327-406.
2. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem 2012;65:329-352.
3. Chiang K, Koo EH. Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol 2014;54:381-405.
4. Bomasang-Layno E, Bronsther R. Diagnosis and treatment of Alzheimer's disease: an update. Dela J Public Health 2021;7:74-85.
5. Ritchie CW, Zhinchin G. Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease. Int Psychogeriatr 2013;25:511-515.
6. Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2018;6:CD001190.
7. Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. Clin Interv Aging 2008;3:211-225.
8. Joe E, Ringman JM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ 2019;367:l6217.
9. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. NMDA receptors: from genes to channels. Trends Pharmacol Sci 1996;17:348-355.
12. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
13. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database Syst Rev 2019;3:CD003154.
16. International Alzheimer’s and Related Dementias Research Portfolio (IADRP). Common Alzheimer's and Related Dementias Research Ontology (CADRO) [Internet]. IADRP; 2020 [cited 2021 Oct 17] Available from:
https://iadrp.nia.nih.gov/about/cadro.
17. Lozupone M, Solfrizzi V, D'Urso F, Di Gioia I, Sardone R, Dibello V, et al. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. Expert Opin Emerg Drugs 2020;25:319-335.
18. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016;537:50-56.
20. Loera-Valencia R, Cedazo-Minguez A, Kenigsberg PA, Page G, Duarte AI, Giusti P, et al. Current and emerging avenues for Alzheimer's disease drug targets. J Intern Med 2019;286:398-437.
21. Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med 2021;384:1691-1704.
23. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 2012;28:49-69.
25. Alexander GC, Emerson S, Kesselheim AS. Evaluation of aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility. JAMA 2021;325:1717-1718.
26. Lee AY. Amyloid-targeting drugs for the treatment of Alzheimer disease. J Korean Neurol Assoc 2021;39:134-140.
28. Moghavem N, Henderson VW, Greicius MD. Medicare should not cover aducanumab as a treatment for Alzheimer's disease. Ann Neurol 2021;90:331-333.
34. Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, et al. ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease. Nat Aging 2021;1:521-534.
35. Qiao O, Ji H, Zhang Y, Zhang X, Zhang X, Liu N, et al. New insights in drug development for Alzheimer's disease based on microglia function. Biomed Pharmacother 2021;140:111703.
36. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol 2018;217:459-472.
37. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci 2013;16:273-280.
38. Morris GP, Clark IA, Zinn R, Vissel B. Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. Neurobiol Learn Mem 2013;105:40-53.
39. Vieira M, Lima-Filho R, De Felice FG. Connecting Alzheimer's disease to diabetes: underlying mechanisms and potential therapeutic targets. Neuropharmacology 2018;136(Pt B):160-171.
40. Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 2012;42:484-491.
41. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 2004;490:115-125.
42. Holscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 2011;39:891-897.
43. Szablewski L. Glucose transporters in brain: in health and in Alzheimer's disease. J Alzheimers Dis 2017;55:1307-1320.
44. Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer's disease a type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol Basis Dis 2017;1863:1078-1089.
45. Kubis-Kubiak AM, Rorbach-Dolata A, Piwowar A. Crucial players in Alzheimer's disease and diabetes mellitus: Friends or foes? Mech Ageing Dev 2019;181:7-21.
46. Salas IH, De Strooper B. Diabetes and Alzheimer's disease: a link not as simple as it seems. Neurochem Res 2019;44:1271-1278.
47. Meng L, Li XY, Shen L, Ji HF. Type 2 diabetes mellitus drugs for Alzheimer's disease: current evidence and therapeutic opportunities. Trends Mol Med 2020;26:597-614.
48. Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer's disease. Ageing Res Rev 2019;54:100936.
49. Holscher C. Brain insulin resistance: role in neurodegenerative disease and potential for targeting. Expert Opin Investig Drugs 2020;29:333-348.
50. Rigotto G, Basso E. Mitochondrial dysfunctions: a thread sewing together Alzheimer's disease, diabetes, and obesity. Oxid Med Cell Longev 2019;2019:7210892.
53. Hill BG, Shiva S, Ballinger S, Zhang J, Darley-Usmar VM. Bioenergetics and translational metabolism: implications for genetics, physiology and precision medicine. Biol Chem 2019;401:3-29.